Most people saw a lawsuit headline this week.

Very few saw the strategic move.

Novo Nordisk dropped its lawsuit against Hims & Hers.

But it came with a condition.

Hims & Hers will stop advertising compounded GLP-1 medications and begin offering Novo’s FDA-approved drugs, including Ozempic and Wegovy, through its platform.

That matters.

For the last two years, telehealth platforms and clinics grew rapidly by offering compounded GLP-1 therapies during the supply shortage. It created an enormous access channel for patients and a massive growth engine for telehealth.

Now the dynamic is shifting.

Instead of trying to shut down telehealth platforms, Novo is pulling them into the distribution channel.

Telehealth is becoming a front door for branded pharma.

This does not mean compounding disappears.

Compounding pharmacies still operate under 503A and 503B rules, and physicians will continue prescribing customized therapies where clinically appropriate.

But it does suggest something important.

The era of mass consumer marketing of compounded GLP-1s through large telehealth platforms may start to shrink as pharmaceutical companies push their own distribution partnerships.

That does not mean demand for metabolic, longevity, and peptide therapies goes away.

In fact, the opposite may happen.

If access to compounded GLP-1s becomes tighter on large platforms, clinics will look more closely at other therapeutic peptides that support recovery, inflammation, metabolic health, and longevity.

And another regulatory factor is sitting in the background.

The FDA’s bulk drug substance list, often referred to in the industry as the “503A list of 17,” has been under review. If more of those substances are ultimately clarified or moved into a compounding-permitted pathway, it could open the door for broader physician use of several peptides that clinics are already studying and prescribing carefully today.

When that happens, the peptide market likely expands in a different direction.

Instead of one dominant class like GLP-1s, you could see a much wider ecosystem of therapies focused on inflammation, immune modulation, tissue repair, mitochondrial health, and metabolic optimization.

So the real signal this week is not simply about GLP-1s.

It is about control of distribution.

Pharma companies are moving upstream to control the digital prescribing channel.

At the same time, physicians and clinics are continuing to explore the broader peptide landscape.

The next phase of this market may be less about one blockbuster molecule and more about a portfolio of targeted therapies.

The GLP-1 wave built the market.

What comes next may diversify it.

The industry keeps talking about GLP-1 drugs as if they were a discovery.

They weren’t.

GLP-1 agonists have been studied since the 1990s and exenatide was approved in 2005. The science was already there. What changed recently was something much more important.

Scale.

Semaglutide and tirzepatide proved that a peptide drug can move beyond specialty endocrinology and become a mass-market therapy generating tens of billions in annual revenue.¹

That moment matters because it solved a question investors and pharmaceutical companies had been asking for years:

Can peptide therapeutics become global blockbusters?

Now the answer is yes.

And once that question was answered, the development pipeline accelerated.

Today more than 100 peptide drugs are approved globally, with hundreds of peptide candidates in clinical development across oncology, metabolic disease, inflammation, and cardiovascular medicine.²

But the real shift is not just in molecule discovery.

It is in drug delivery and manufacturing.

Historically peptides faced three major barriers:

• short half-life
• enzymatic degradation
• poor oral bioavailability

Advances in peptide engineering are rapidly changing that.

Researchers are now using lipidation, albumin binding, PEGylation, and backbone modifications to extend half-life and stabilize molecules in circulation. These technologies are the same structural innovations that allowed semaglutide to become a once-weekly therapy.³

At the same time, pharmaceutical companies are investing heavily in oral peptide delivery platforms, permeability enhancers, and nanoparticle carriers that allow peptides to survive the gastrointestinal tract.

Novo Nordisk’s oral semaglutide is one of the first major proofs that peptide drugs can move beyond injections when paired with absorption-enhancing technologies.⁴

What this means in practical terms is simple.

The constraints that historically limited peptide therapeutics are disappearing.

And when delivery barriers fall, biology becomes the limiting factor.

Which is why the pipeline is expanding rapidly into areas that were previously difficult to drug effectively with small molecules.

Current peptide development programs are exploring targets across:

• mitochondrial signaling pathways
• inflammatory cytokine cascades
• neuropeptide systems
• regenerative and tissue repair mechanisms
• immune modulation pathways

This is where the GLP-1 conversation becomes too narrow.

GLP-1 drugs did not create the peptide era.

They validated it.

Once a therapeutic class proves it can generate multi-billion-dollar drugs with strong safety profiles and clear mechanisms of action, capital floods into adjacent pathways.

That is exactly what is happening now.

The next decade of pharmaceutical development will likely see a wave of peptide-based therapeutics expanding well beyond metabolic disease.

GLP-1s were simply the first peptide class to reach global scale.

They will not be the last.

Sources…

I've spent the past decade building and scaling operations across clinics, telehealth platforms, and compounding pharmacies. I've seen practices succeed at 20 patients per month and break at 200. I've watched regulatory shifts reorganize entire markets overnight. I've built the infrastructure that determines whether modern therapies scale or stall.

This newsletter is about understanding how the system actually functions, where friction hides, and why some approaches compound over time while others don't.

If you're building, running, or participating in modern health in any real way, this layer matters more than most people realize.